Prosecution Insights
Last updated: April 19, 2026
Application No. 18/286,049

ENDOPROTHESES COMPONENT FOR JOINTS

Non-Final OA §102§112
Filed
Oct 06, 2023
Examiner
PRESTON, REBECCA STRASZHEIM
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Semmelweis Egyetem
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
3y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
453 granted / 616 resolved
+3.5% vs TC avg
Strong +37% interview lift
Without
With
+37.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
28 currently pending
Career history
644
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
28.7%
-11.3% vs TC avg
§102
33.1%
-6.9% vs TC avg
§112
32.4%
-7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 616 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The disclosure is objected to because of the following informalities: “voronoi” is consistently misspelled as “voronoy”. Appropriate correction is required. Claim Objections Claim(s) 1-2 is/are objected to because of the following informalities: Within claim 1, line 4: “a counter component” should be replaced with --the counter component (1,2)-- to properly mirror the counter component within claim 1, lines 2-3. Within claim 2: “Voronaj” is misspelled (it should be Voronoi). Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim(s) 1-6 is/are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites the limitation "the friction surface" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim(s) 2-6, which depend from claim 1, inherit all the problems associated with claim 1. Within claim 1, line 3: Applicant claims, “side joint”; it is unclear, and therefore indefinite, which joint (singular) is being referred to from the plurality of joints within claim 1, lines 1-2 (appropriate correction will also be required within claim 1, lines 4-5). Within claim 1, lines 1-4: Applicant claims, “a frictional surface (1a, 2a) […] characterized in that a cell structure (9) having a predetermined thickness is formed ON the frictional surface (1a, 2a)”; it is unclear, and therefore indefinite, how the frictional surface can be BOTH characterized with (be defined by) a predetermined thickness and ON itself – instead wouldn’t the frictional surface (which features a cell structure) have a predetermined thickness (but is not ON itself). Within claim 5, lines 2-3: Applicant claims, “it is made of”; it is unclear, and therefore indefinite, what “it” is – the friction surface alone OR the entire articular endoprosthesis component. Within claim 6, line 2: Applicant claims, “it is made of”; it is unclear, and therefore indefinite, what “it” is – the friction surface alone OR the entire articular endoprosthesis component. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-4 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Holmes et al. (US 2021/0298909 A1). With respect to claim 1: Holmes et al. discloses an articular endoprosthesis component (1, 2) (tissue scaffold) for joints having a friction surface (1a, 2a) (tissue scaffold is implanted on an articulating surface of a knee; as such, the outer most region thereof, which is configured to contact the tibia, will define a “frictional surface”), as can be seen in fig. 8, which can be (is capable of being) fitted to a friction surface of a counter component (1,2) (the counter component is not positively recited by Applicant, however, the tissue scaffold is capable of use with a tibial plate/ insert) of said joint (knee), characterized in that a cell structure (9) (pores of tissue scaffold) having a predetermined thickness (thickness of layers/ regions of the tissue scaffold) is formed on the friction surface (1a, 2a) (tissue scaffold is implanted on an articulating surface of a knee; as such, the outer most region thereof, which is configured to contact the tibia) to be fitted to (is capable of being fitted to) a counter component of the joint (paragraphs [0074, 0182, 0184-0195]). With respect to claim 2: Wherein the cell structure (9) (pores) comprises Voronoi cells (Voronoi structures) (paragraph [0074]). With respect to claim 3: Wherein the cell structure (9) (pores) comprises first cells (7) (pores within first region) and second cells (8) (pores within second region) (paragraphs [0075, 0082]), wherein characteristic dimension of the first cells (7) (pore width within first region) is preferably in a range from 5 µm to 100 µm (0-50 µm) (paragraph [0082]); and the characteristic dimension of the second cells (8) (pore width within second region) is preferably from 100 µm to 300 µm (100-200 µm) (paragraph [0082]). With respect to claim 4: Wherein the cell structure (9) has a thickness (the thickness of one of the regions with pores) of a range between 0.5 mm and 10 mm (0.1-5 mm) (paragraph [0079]). Claim(s) 1, 6 is/are rejected under 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) as being anticipated by Chan et al. (US 6866685B2). With respect to claim 1: Chan et al. discloses an articular endoprosthesis component (1, 2) (bearing component 10, as can be seen in figs. 1-2, or bearing component 600, as can be seen in fig. 9) for joints having a friction surface (1a, 2a) (surface 24, 606), which can be fitted to the friction surface of a counter component (1,2) (femoral head) of said joint (column 6, lines 41-57, column 9, line 52-column 10, line 19), characterized in that a cell structure (9) (recesses 32 or micro recesses 614) having a predetermined thickness (depth) is formed on the friction surface (1a, 2a) (surface 24, 606) to be fitted to a counter component (femoral head) of the joint (column 7, line 27-column 4, line 44, column 9, line 52-column 10, line 19). With respect to claim 6: Wherein the articular endoprosthesis component (1, 2) (bearing component 10, as can be seen in figs. 1-2, or bearing component 600, as can be seen in fig. 9) is made of a material selected from the group consisting of polyethylene (UHMWPE) and poly(ether-ether ketone) 9column 7, lines 9-27). Claim(s) 1, 5 is/are rejected under 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) as being anticipated by Collier (4156943). With respect to claim 1: Collier discloses an articular endoprosthesis component (1, 2) (ball joint 101), as can be seen in fig. 1, for joints having a friction surface (1a, 2a) (articulation surface), which can be fitted to the friction surface of a counter component (1,2) (Applicant has not positively recited the counter component nor the friction surface thereof, as such, the articulation surface of the ball joint 101 is capable of being fitted therewith) of said joint (column 2, line 56-column 3, line 24, column 3, lines 43-51), characterized in that a cell structure (9) (pores) having a predetermined thickness (the thickness through of a portion of the articulating surface with pores) is formed on the friction surface (1a, 2a) (articulation surface) to be fitted to a counter component of the joint (Applicant has not positively recited the counter component nor the friction surface thereof, as such, the articulation surface of the ball joint 101 is capable of being fitted therewith). With respect to claim 5: Wherein articular endoprosthesis component (1, 2) (ball joint 101) is made of titanium alloy or medical steel (titanium or low carbon stainless steel) (column 4, lines 27-34). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA S PRESTON whose telephone number is (571)270-5233. The examiner can normally be reached M, W: 9-5; T, Th, F: 9-1. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jerrah Edwards can be reached at (408)918-7557. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA S PRESTON/ Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Oct 06, 2023
Application Filed
Feb 05, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599468
DEPLOYMENT OF MULTIPLE BILIARY STENTS
2y 5m to grant Granted Apr 14, 2026
Patent 12594163
Tissue Gripper and Valve Clamping Device
2y 5m to grant Granted Apr 07, 2026
Patent 12569233
DEVICES AND METHODS FOR CORONARY SINUS PRESSURE RELIEF
2y 5m to grant Granted Mar 10, 2026
Patent 12564486
DEVICES AND METHODS FOR TREATING AN ANEURYSM
2y 5m to grant Granted Mar 03, 2026
Patent 12558240
Aortic ARCH Baroreceptor Implants for Treatment of Hypertension
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+37.1%)
3y 7m
Median Time to Grant
Low
PTA Risk
Based on 616 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month